Southern RNA products are designed to support the full spectrum of RNA therapeutic and vaccine development. From early research through to clinical manufacturing, our plasmid DNA and mRNA materials enable innovators to progress programmes with confidence, consistency, and regulatory alignment.
Our research-grade plasmid DNA and mRNA support construct validation, in vitro testing, and early proof-of-concept studies. High purity and reproducibility ensure reliable experimental outcomes and faster iteration during discovery phases.
Preclinical programs benefit from scalable production of research and GMP-aligned grade nucleic acids as they advance toward translational milestones. Southern RNA’s process development and analytical services help ensure consistency, purity, and suitability for later stages of evaluation.
GMP-aligned and clinical-grade products are used to support early-phase trials, including first-in-human studies. Manufactured under controlled systems with comprehensive documentation, they are suitable for regulatory submission and audit review.
Our plasmid DNA and mRNA products are utilised in vaccine platforms, oncology therapeutics, rare disease programmes, and other emerging RNA-based modalities, where performance, purity, and reliability are critical.
Southern RNA provides high-quality plasmid DNA and mRNA products for research and clinical applications. Our scalable production ensures consistent quality and performance, helping scientists accelerate RNA-based therapies.
Discover our co-transcriptional capping reagent for mRNA and lower the cost of your IVT.
Quality is central to Southern RNA. Our Quality Management System supports GMP operations and early-phase clinical manufacturing. From raw material qualification to final product release, every step follows documented procedures and risk assessments to ensure consistency and patient safety.
Compliance is embedded in our workflows, not just a final checkpoint. We maintain documentation systems, change management processes, and analytical verification to support regulatory submissions. By aligning quality oversight with execution, we help clients progress confidently from research to clinical supply.
We leverage state-of-the-art technologies and proprietary platforms to deliver reproducible and scalable outcomes tailored to complex RNA-based projects. Our technical capabilities include:
Analytical tools and PAT support characterisation of pDNA and mRNA products, including purity profiling and identity testing, essential for quality documentation.
We use advanced in vitro transcription and RNA clearance methods to improve safety and performance.
We supply materials like Co Cap™ and GMP-aligned plasmid DNA to enhance efficiency and streamline production.
Our flexible infrastructure adapts to your project’s scale without compromising quality or timeline.
